bmy888 download
Quest Partners LLC lifted its position in shares of Gilead Sciences, Inc. ( NASDAQ:GILD – Free Report ) by 163.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,400 shares of the biopharmaceutical company’s stock after acquiring an additional 5,211 shares during the period. Quest Partners LLC’s holdings in Gilead Sciences were worth $704,000 as of its most recent filing with the Securities & Exchange Commission. Several other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. Concord Asset Management LLC VA raised its stake in shares of Gilead Sciences by 3.8% in the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 111 shares during the last quarter. TFB Advisors LLC raised its position in Gilead Sciences by 1.2% in the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock worth $788,000 after buying an additional 116 shares during the last quarter. Sumitomo Life Insurance Co. lifted its stake in Gilead Sciences by 0.7% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock valued at $1,494,000 after acquiring an additional 117 shares during the period. FDx Advisors Inc. boosted its holdings in shares of Gilead Sciences by 2.2% during the 3rd quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company’s stock valued at $450,000 after acquiring an additional 117 shares during the last quarter. Finally, Sivia Capital Partners LLC grew its stake in shares of Gilead Sciences by 3.9% in the third quarter. Sivia Capital Partners LLC now owns 3,249 shares of the biopharmaceutical company’s stock worth $272,000 after acquiring an additional 123 shares during the period. 83.67% of the stock is owned by institutional investors. Gilead Sciences Price Performance GILD stock opened at $90.19 on Friday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The company’s fifty day moving average price is $87.43 and its 200-day moving average price is $76.79. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90. The company has a market capitalization of $112.40 billion, a PE ratio of 1,002.11, a price-to-earnings-growth ratio of 2.72 and a beta of 0.17. Gilead Sciences Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.42%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%. Analyst Ratings Changes Several brokerages recently issued reports on GILD. Barclays raised their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. BMO Capital Markets lifted their price objective on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Wolfe Research initiated coverage on Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 target price on the stock. Royal Bank of Canada boosted their price target on Gilead Sciences from $81.00 to $84.00 and gave the company a “sector perform” rating in a research note on Monday, November 18th. Finally, Truist Financial increased their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Twelve investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $95.41. Check Out Our Latest Stock Analysis on GILD Insider Transactions at Gilead Sciences In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This represents a 1.96 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 27.31 % decrease in their position. The disclosure for this sale can be found here . Insiders have sold 56,947 shares of company stock valued at $4,968,674 in the last ninety days. Corporate insiders own 0.16% of the company’s stock. Gilead Sciences Profile ( Free Report ) Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. Read More Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. ( NASDAQ:GILD – Free Report ). Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter .Percentages: FG .418, FT .750. 3-Point Goals: 10-26, .385 (Butler 5-9, Campbell 2-3, Khayat 1-2, M.Johnson 1-4, Thomas 1-7, Exacte 0-1). Team Rebounds: 1. Team Turnovers: 1. Blocked Shots: 1 (Towns). Turnovers: 10 (Campbell 4, M.Johnson 3, Butler, Felt, Towns). Steals: 6 (Campbell 2, Green, Khayat, M.Johnson, Thomas). Technical Fouls: None. Percentages: FG .500, FT .909. 3-Point Goals: 8-20, .400 (Karasinski 2-4, Smith 2-4, B.Johnson 2-6, Hopf 1-1, Branson 1-2, Goodin 0-1, Hacker 0-2). Team Rebounds: 0. Team Turnovers: 1. Blocked Shots: 4 (Branson 2, Hacker 2). Turnovers: 9 (Branson 2, Hopf 2, B.Johnson, Hacker, Karasinski, Smith, Whitaker). Steals: 6 (Smith 3, Doyle, Hopf, Karasinski). Technical Fouls: None. A_1,282 (2,196).
Stock market today: Wall Street slips as the 'Magnificent 7' weighs down the marketAdani Group faces potential US market restrictions amid indictment: ExpertBlackrock® Canada Announces Final Annual Reinvested Capital Gains Distributions For The Ishares® Etfs
President-elect Donald Trump announced the death of attorney David B. Rivkin Jr. on Truth Social. Trump described Rivkin as a "superstar," stating, "He was a great lawyer, scholar, and defender of mine." Trump extended condolences to Rivkin’s wife, Diana, and family, calling him a loss that will be "greatly missed." Who Was David B. Rivkin?David B. Rivkin Jr. was a notable lawyer and legal academic. He served as a partner at BakerHostetler LLP, co-leading the firm's appellate and major motions group. Rivkin focused on constitutional, administrative, and international law, managing prominent cases during his career. Rivkin received national fame as the head lawyer representing 26 states contesting the legality of the Affordable Care Act. This case arrived at the Supreme Court in 2012 and signified a crucial point in his career. He also represented Croatia at the International Criminal Tribunal and the International Court of Justice. His research concentrated on international humanitarian law and wartime regulations, covering numerous years and intricate topics. Rivkin's knowledge encompassed national security matters. He represented former Defense Secretary Donald Rumsfeld in legal cases and oversaw matters related to Bivens actions. Furthermore, he handled legal cases concerning the Foreign Corrupt Practices Act, compliance with sanctions, and environmental laws. Between 2004 and 2007, Rivkin acted as an expert member of the United Nations Subcommission on Human Rights. He provided guidance on international law and aided global human rights efforts. While President George H.W. Bush was in office, Rivkin was instrumental in regulatory reform. In his role as Special Assistant for Domestic Policy, he managed initiatives aimed at reducing regulations related to energy and the environment. He played a key role in formulating Order 636, which revamped regulations for natural gas pipelines. Rivkin also occupied important roles in the Department of Energy, concentrating on energy and environmental law. His duties encompassed formulating climate change policies, executing clean energy initiatives, and tackling international regulatory issues. In addition to litigation, Rivkin worked as Legal Advisor to the Counsel for Vice President George H.W. Bush. His professional journey included positions in the White House Counsel’s Office and the Department of Justice, where he contributed to the development of energy and environmental policy. Get Latest News Live on Times Now along with Breaking News and Top Headlines from US News, World and around the world.Noonan: ‘We Are Back to the Island of Misfit Toys’Navy gets 95-yard TD run from Horvath and stops 2-point try to beat Oklahoma in Armed Forces BowlLeBlanc and Joly offer little details about visit with Trump's team in Florida
Let us reflect, refocus and rebuild our party – Kwaku Appiah urges NPP membersMUMBAI: The BJP’s Colaba MLA Rahul Narwekar is set to be elected speaker of the assembly for the second time, a record hitherto held only by Congress MLA Balasaheb Bharde in the sixties. Narwekar’s appointment will be officially announced on Monday. On the day of filing nominations for the post of the speaker of the 15th Maharashtra legislative assembly, Narwekar’s was the only application received by returning officer Jitendra Bhole. The opposition does not have the adequate strength to claim the post. Pro-tem speaker Kalidas Kolambkar will complete the procedure by announcing Narwekar’s name in the lower house on the last day of the three-day special session. The MLA on Sunday claimed that nobody could point a finger at the decisions taken and rulings given by him in his first term as speaker. “The second term too will be dedicated to the people of the state by focusing on justice for them,” he said. “It will be an impartial tenure and I seek the cooperation of all my fellow MLAs in the lower house.” Narwekar is the second MLA to serve two terms in the speaker’s chair. Balasaheb alias Trimbak Bharde, a Gandhian and Congress leader who represented Shevgaon in Ahmednagar, served as the speaker from 1962 to 1972. Narwekar served a two-and-a-half-year term from July 3, 2022 and was the second-youngest speaker when elected to the post. Shivaraj Chakukar Patil was the youngest speaker of Maharashtra when he was elected to the post in March 1978. He was 42 then. Narwekar, 47, was a practising lawyer in the Bombay high court and is a two-term MLA from Colaba in South Mumbai. Son-in-law of senior NCP leader and former legislative council chairperson Ramraje Naik Nimbalkar, he began his political career as the Shiv Sena spokesperson in 1999. He quit the Sena in 2014 after he was denied a Lok Sabha ticket and joined the NCP, subsequently contesting the Lok Sabha polls unsuccessfully from Maval. In 2019, he joined the BJP and contested from the Colaba assembly constituency, winning as an MLA for the first time. In his election affidavit in November this year, Narwekar announced his assets as ₹ 129.81 crore, up from ₹ 38.09 crore in 2019 and ₹ 10 crore in 2014. His younger brother Makrand and sister-in-law Harshita were former BMC corporators from Colaba and Cuffe Parade while his father, Suresh Narwekar, was also a councillor from Colaba. During his tenure, Narwekar delivered two important judgments. The Shiv Sena and NCP had been vertically split in June 2022 and July 2023 respectively and Narwekar, as the speaker, held hearings to decide on the “real” Shiv Sena and NCP on the directions of the Supreme Court. He ruled that the breakaway factions of the Sena under Eknath Shinde and the NCP under Ajit Pawar were the real parties, and the name and symbol of the undivided parties was allotted to them. The MLA is also heading a committee to look into the constitutional provisions that deal with the defection of MLAs and MPs in the anti-defection law. The committee was announced by Lok Sabha speaker Om Birla in January this year. The Shiv Sena too was reportedly demanding the speaker’s post as part of the power-sharing pact between the three ruling parties. However, the BJP retained the post, and picked Narwekar for it for the second consecutive time. Another name being considered was that of senior BJP legislator Sudhir Mungantiwar. “But the party leadership thinks that Narwekar is the best choice for the post, given his ruling in the disqualification petitions related to the Shiv Sena and NCP,” said a BJP leader. “Although he was eyeing a ministerial berth, there aren’t enough berths from Mumbai to accommodate him.” Narwekar was also interested in contesting the Lok Sabha election from Mumbai South, but the seat went to the Shiv Sena in the seat-sharing pact.
Thrivent Financial for Lutherans Decreases Position in LKQ Co. (NASDAQ:LKQ)
Stock market today: Wall Street slips as the 'Magnificent 7' weighs down the market
Chase Artopoeus has two TD passes, TD run as Chattanooga tops Austin Peay 24-17 in season finale
Tallinn (Estonia), Nov 23 (AP) Belarus has granted asylum to a former Polish judge who faced espionage charges at home following his defection in May to the Kremlin-allied country. A decree published on Friday by Alexander Lukashenko, Belarus' autocratic president, described Tomasz Szmydt as being “prosecuted for political reasons” in Poland. The country is an EU and NATO member that has lent vocal support to Ukraine in its war against Russian aggression. Also Read | Pakistan Violence: 15 Killed, 25 Injured in Fresh Sectarian Clashes in Kurram, 2 Days After Attack on Passenger Vehicles. Szmydt's defection to Belarus in May trained the focus on Poland as a key target for Russian intelligence activity and ignited a bitter political row over the circumstances of his rapid ascent through the ranks of the Polish justice system. Poland's prosecutors and special services launched an investigation the same month after Belarus media reported that Szmydt arrived in the country and asked for protection. Warsaw responded days later by putting Szmydt on a wanted list, a step toward an international arrest warrant on spying allegations that would restrict his ability to travel internationally. Also Read | Gautam Adani Indicted: US SEC Summons Indian Billionaire's Nephew Sagar in Bribery Case. Polish officials have been working to determine how harmful Szmydt's knowledge of any classified information might be to the interests of Warsaw and its Western allies. Poland's Prime Minister Donald Tusk has publicly called him a traitor. Szmydt fled to Belarus after resigning from his post as a judge at the Warsaw Administrative Court, saying in a public statement that he was doing so in protest against Poland's “harmful and unjust” policy toward Belarus and Russia. A short time later, he appeared at a press conference in Belarus, praising Lukashenko's regime and presenting himself as a victim of repression. A Polish court later that month lifted Szmydt's immunity, allowing him to be tried in absentia for spying allegations that he has denied. Szmydt was notorious in Poland for having engaged in a 2019 online smear campaign against other judges that was sponsored by the Justice Ministry under the previous right-wing government. Three years later, he appeared to switch sides, appearing in a TV documentary to expose what he said was unethical behaviour by judges close to the ruling party. Szmydt's defection came as a shock in Poland, which has a history of distrust of Russia. Belarus has been one of the Kremlin's few close allies since Russia's full-scale invasion of Ukraine in February 2022, and Lukashenko has relied on Moscow's subsidies and support. In return, he has allowed Moscow to use Belarusian territory to send troops and weapons into the neighbouring state, and to deploy tactical nuclear weapons on Belarusian soil. Authorities in Minsk have been ratcheting up repressive measures ahead of a presidential election in January in which the strongman leader is seeking a seventh term, including by arresting hundreds of people who have shown solidarity with Kyiv. Authorities responded to massive protests following the widely disputed 2020 election of Lukashenko with a wide-ranging crackdown in which about 65,000 people were arrested. Major opposition figures were either imprisoned or fled the country, and human rights activists say Belarus is holding about 1,300 political prisoners. (AP) (This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)AHL Glance
Investors with a lot of money to spend have taken a bearish stance on Goldman Sachs Gr GS . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GS, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga 's options scanner spotted 51 uncommon options trades for Goldman Sachs Gr. This isn't normal. The overall sentiment of these big-money traders is split between 25% bullish and 49%, bearish. Out of all of the special options we uncovered, 8 are puts, for a total amount of $470,050, and 43 are calls, for a total amount of $3,308,371. Expected Price Movements Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $150.0 to $600.0 for Goldman Sachs Gr over the last 3 months. Insights into Volume & Open Interest Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Goldman Sachs Gr's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Goldman Sachs Gr's substantial trades, within a strike price spectrum from $150.0 to $600.0 over the preceding 30 days. Goldman Sachs Gr Call and Put Volume: 30-Day Overview Largest Options Trades Observed: Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume GS CALL TRADE BEARISH 01/17/25 $432.4 $426.35 $428.69 $150.00 $428.6K 2 16 GS CALL TRADE BEARISH 01/17/25 $432.35 $426.05 $428.56 $150.00 $428.5K 2 26 GS CALL TRADE BEARISH 01/17/25 $428.75 $422.75 $424.48 $155.00 $254.6K 0 38 GS CALL TRADE BEARISH 01/17/25 $428.2 $422.75 $424.66 $155.00 $212.3K 0 21 GS CALL TRADE BEARISH 01/17/25 $428.2 $422.75 $424.71 $155.00 $169.8K 0 16 About Goldman Sachs Gr Goldman Sachs is a leading global investment banking and asset management firm. Approximately 20% of its revenue comes from investment banking, 45% from trading, 20% from asset management and 15% from wealth management and retail financial services. Around 60% of the company's net revenue is generated in the Americas, 15% in Asia, and 25% in Europe, the Middle East, and Africa. After a thorough review of the options trading surrounding Goldman Sachs Gr, we move to examine the company in more detail. This includes an assessment of its current market status and performance. Where Is Goldman Sachs Gr Standing Right Now? Currently trading with a volume of 912,290, the GS's price is up by 2.23%, now at $583.5. RSI readings suggest the stock is currently is currently neutral between overbought and oversold. Anticipated earnings release is in 22 days. What Analysts Are Saying About Goldman Sachs Gr A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $614.6666666666666. Unusual Options Activity Detected: Smart Money on the Move Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access .* An analyst from HSBC downgraded its action to Hold with a price target of $608. * An analyst from Keefe, Bruyette & Woods persists with their Outperform rating on Goldman Sachs Gr, maintaining a target price of $686. * An analyst from JP Morgan has decided to maintain their Overweight rating on Goldman Sachs Gr, which currently sits at a price target of $550. Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Goldman Sachs Gr options trades with real-time alerts from Benzinga Pro . © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.A cafe has been put up for sale just six months after opening its doors. Eatery, on Minard Road in the , has hit the market for offers over £35,000. The business opened in March, but announced on social media they were to temporarily close on October 27 for "important maintenance" and would re-open 'soon'. It now appears those plans have been dashed, with the cafe being offered for sale. According to the advert, it seats 18 people and has a class 1 use - serving coffee alongside a 'modern menu'. The reads: "The Business Sales Agency is pleased to bring to the market this excellent opportunity to acquire a popular café in the densely populated Shawlands area of Glasgow’s South Side. "Bright spacious recently refurbished unit with front seating and counter area with kitchen and toilet to the rear. This is an excellent opportunity to acquire a popular café in the densely populated Shawlands of Glasgow’s South Side. "Shawlands attracts a healthy mix of students, young professionals and families which enjoy its active café culture. With a large number of residents working on a hybrid basis and from home it provides a regular customer base for sit in and delivery trade. "With its fresh décor and open plan layout this business is ideally suited to both daytime and early evening custom."
NoneInvestigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis